| P50 | author | Hidekatsu Iha | Q55271494 |
| | Naoki Hijiya | Q89308701 |
| | Kazunari Murakami | Q98167151 |
| | Kuniaki Shirao | Q115365988 |
| | Masatsugu Moriyama | Q115626768 |
| | Keiko Matsuura | Q115626771 |
| | Yoshiyuki Tsukamoto | Q115626775 |
| | Tomohisa Uchida | Q115626776 |
| P2093 | author name string | Kazuyoshi Yanagihara | |
| | Masataka Seike | |
| | Tsutomu Daa | |
| | Masaaki Kodama | |
| | Tadayoshi Okimoto | |
| | Shoichi Fumoto | |
| | Chisato Nakada | |
| | Yuka Hirashita | |
| P2860 | cites work | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers | Q26781362 |
| | Targeting receptor tyrosine kinases in gastric cancer | Q27013050 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212 | Q27851693 |
| | Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. | Q27852991 |
| | RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells | Q27853064 |
| | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 |
| | Defining the role of mTOR in cancer | Q28235431 |
| | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 |
| | Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 |
| | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 |
| | Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | Q29614280 |
| | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 |
| | mTOR signaling at a glance | Q29619857 |
| | Identification of a novel human ankyrin-repeated protein homologous to CARP. | Q30687802 |
| | Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 |
| | S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 |
| | Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) | Q34669648 |
| | A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets | Q35878807 |
| | A unifying model for mTORC1-mediated regulation of mRNA translation. | Q35945036 |
| | HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 |
| | TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma | Q37401151 |
| | Translational control in cancer. | Q37717999 |
| | MEK inhibitor for gastric cancer with MEK1 gene mutations. | Q38953493 |
| | KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer | Q39860040 |
| | Identification of a conserved motif required for mTOR signaling | Q40736711 |
| | Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. | Q41511697 |
| | Establishment and characterization of a human gastric scirrhous carcinoma cell line in serum-free chemically defined medium | Q41554018 |
| | Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice | Q42800324 |
| | Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene | Q42808616 |
| | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 |
| | BRAF and KRAS mutations in stomach cancer | Q44611189 |
| | Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. | Q44952322 |
| | ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. | Q45954184 |
| | Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1 | Q70122834 |
| | Trastuzumab in the treatment of breast cancer | Q81374982 |
| P433 | issue | 12 | |
| P921 | main subject | phosphorylation | Q242736 |
| P304 | page(s) | 1919-1928 | |
| P577 | publication date | 2016-10-03 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells | |
| P478 | volume | 107 | |